Floatz logo

Alobresib

Advanced Estrogen Receptor Positive HER2- Breast Cancer

Gilead SciencesSmall moleculePhase 1/2Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

77 Active assets in the Advanced Estrogen Receptor Positive HER2- Breast Cancer cohort.

Asset / SponsorPhaseRating
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 4BBB
EXEMESTANE
National Cancer Institute (NCI)
Phase 4BBB
Everolimus
UNC Lineberger Comprehensive Cancer Center
Phase 4BBB
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 4BB
Palbociclib
Forward Pharmaceuticals Co., Ltd.
Phase 3BB

View all 50 →

Same molecule, other indications

Alobresib is also rated in:

metastatic prostate carcinomaDormant
C
Indicative ·
39 / 100
View asset →
hematopoietic and lymphoid system neoplasmDormant
C
Indicative ·
38 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →